Medicamental treatment of Itsenko-Cushing’s disease. The current state-of-the art

Itsenko-Cushing’s disease (ICD) is a severe progressive neuroendocrine pathology characterized by the heterogeneous clinical picture and the high risk of complications. The main goals of ICD therapy include the total removal or the pituitary neoplasm or the reduction of its volume and/or stabilization of its growth, normalization of the cortisol level and secretion rhythm, the achievement of reverse development of clinical manifestations, and the retention of the pituitary hormonal function with a minimal risk of relapses. At present, both the improved methods for diagnostics of ICD and the development of its pharmacotherapy are needed. In the routine clinical practice, ICD is usually treated with the medicines of the following groups: blockers of glucocorticoid receptors and steroidogenesis, dophamine receptor antagonists, and multi-ligand somatostatin analogs. The evidence-based substantiation for the use of the above preparations was provided by the retrospective studies with the description of a series of cases which substantially restricts the reliable interpretation of the data on the effectiveness and safety of various medicines applied to manage the patients presenting with Itsenko-Cushing’s disease. The multi-ligand somatostatin analog pasiretoide is the sole preparation approved for the treatment of adult patients suffering ICD whose surgical treatment is either ineffective or impossible. The evaluation of the effectiveness and safety of pasiretoide therapy is based on the results of the prospective randomized double-blind classical study in which two doses of pasiretoide were used. By month 6 after the onset of the treatment with pasiretoide, the median of the daily decrease of the urinary cortisol level in the patients with ICD was 47.9%. The safety profile of this medication proved to be similar with that of other somatostatin analogs, with the exception of the higher frequency of hyperglycemia. Pasiretoide, like other somatostatin analogs, most frequently caused such adverse reactions as gastrointestinal disorders. At the same time, it ensured the stable reduction of the cortisol level by suppressing the ACTH production, and thereby decreased the main manifestations of hypercortisolism, induced clinical and hormonal remission, and improved the quality of life of the patients suffering Itsenko-Cushing’s disease.

Itsenko-Cushing’s disease, multi-ligand somatostatin analog, pituitary adenoma, hypercortisolism, pasiretoide, cabergolin

1. Дедов И.И., Мельниченко Г.А., Марова Е.И., Арапова С.Д., Белая Ж.Е., Рожинская Л.Я., и др. Болезнь Иценко-Кушинга: клиника, диагностика, лечение. / Под редакцией Дедова И.И., Мельниченко Г.А. Практическое руководство для врачей. – М.; 2012. [Dedov II, Mel'nichenko GA, Marova EI, Arapova SD, Belaya ZE, Rozhinskaya LY, et al. Cushing's disease: clinical features, diagnosis, treatment. Ed by Dedov I.I., Melnichenko G.A. A practical guide for physicians. - Moscow; 2012.]

2. Feelders RA, Pulgar SJ, Kempel A, Pereira AM. MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects. European Journal of Endocrinology. 2012;167(3):311-326. doi: 10.1530/eje-11-1095

3. Белая Ж.Е., Рожинская Л.Я., Мельниченко Г.А., Дедов И.И. Современный взгляд на скрининг и диагностику эндогенного гиперкортицизма. // Проблемы эндокринологии. – 2012. – Т. 58. – №4. – С. 35-41. [Belaia ZE, Rozhinskaia LI, Mel'nichenko GA, Dedov II. Current views of the screening and diagnostics of endogenous hypercorticism. Problemy Endokrinologii. 2012;58(4):35-41.] doi: 10.14341/probl201258435-41

4. Белая Ж.Е., Ильин А.В., Мельниченко Г.А., Рожинская Л.Я., Драгунова Н.В., Дзеранова Л.К., и др. Автоматизированный электрохемилюминесцентный метод определения кортизола в слюне для диагностики эндогенного гиперкортицизма среди пациентов с ожирением. // Ожирение и метаболизм. – 2011. – №2. – С. 56-63. [Belaya ZE, Il'in AV, Mel'nichenko GA, Rozhinskaya LY, Dragunova NV, Dzeranova LK, et al. Avtomatizirovannyy elektrokhemilyuminestsentnyy metod opredeleniya kortizola v slyune dlya diagnostiki endogennogo giperkortitsizma sredi patsientov s ozhireniem. Obesity and metabolism. 2011;(2):56-63.] doi: 10.14341/2071-8713-4954

5. Белая Ж.Е., Рожинская Л.Я., Драгунова Н.В., Дзеранова Л.К., Марова Е.И., Арапова С.Д., и др. Метаболические осложнения эндогенного гиперкортицизма. Выбор пациентов для скрининга. // Ожирение и Метаболизм. – 2013. – №1. – С. 26-31. [Belaya ZE, Rozhinskaya LY, Dragunova NV, Dzeranova LK, Marova EI, Arapova SD, et al. Metabolic complications of endogenous Cushing: patient selection for screening. Obesity and metabolism. 2013;(1):26-31.] doi: 10.14341/2071-8713-5068

6. Valassi E, Santos A, Yaneva M, Toth M, Strasburger CJ, Chanson P, et al. The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology. 2011;165(3):383-392. doi: 10.1530/eje-11-0272

7. Rozhinskaya L, Pigarova EA, Belaya ZE, Dzeranova LK, Molitvoslovova NN, Melnichenko GA, et al. Russian Registry of Patients with Tumors of the Hypothalamic-Pituitary Region (OGGO): October 2013 Update for Cushing's Disease. Cushing's and Non Functional Tumors. p. SAT-0643-SAT-0643. Available from: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2014.NP.4.SAT-0643

8. Gadelha MR, Vieira Neto L. Efficacy of medical treatment in Cushing's disease: a systematic review. Clinical Endocrinology. 2014;80(1):1-12. doi: 10.1111/cen.12345

9. McKeage K. Pasireotide: A Review of Its Use in Cushing’s Disease. Drugs. 2013;73(6):563-574. doi: 10.1007/s40265-013-0052-0

10. Morgan FH, Laufgraben M. Medical management of Cushing’s syndrome. Expert Review of Endocrinology & Metabolism. 2013;8(2):183-193. doi: 10.1586/eem.13.3

11. Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and Morbidity in Cushing's Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature. The Journal of Clinical Endocrinology & Metabolism. 2011;96(3):632-642. doi: 10.1210/jc.2010-1942

12. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JHC, et al. Mortality in Patients Treated for Cushing’s Disease Is Increased, Compared with Patients Treated for Nonfunctioning Pituitary Macroadenoma. The Journal of Clinical Endocrinology & Metabolism. 2007;92(3):976-981. doi: 10.1210/jc.2006-2112

13. Dekkers OM, Horváth-Puhó E, Jørgensen JOL, Cannegieter SC, Ehrenstein V, Vandenbroucke JP, et al. Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study. The Journal of Clinical Endocrinology & Metabolism. 2013;98(6):2277-2284. doi: 10.1210/jc.2012-3582

14. Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of Adrenocorticotropin-Dependent Cushing’s Syndrome: A Consensus Statement. The Journal of Clinical Endocrinology & Metabolism. 2008;93(7):2454-2462. doi: 10.1210/jc.2007-2734

15. Нейроэндокринология: клинические очерки. / Под редакцией профессора, лауреата Государственной премии СССР Маровой Е.И. – Ярославль: "ДИА-пресс"; 1999. [ Neuroendocrinology: clinical essays. / Ed by Marova E.I. Yaroslavl: "DIA-press"; 1999.]

16. Patil CG, Prevedello DM, Lad SP, Vance ML, Thorner MO, Katznelson L, et al. Late Recurrences of Cushing’s Disease after Initial Successful Transsphenoidal Surgery. The Journal of Clinical Endocrinology & Metabolism. 2008;93(2):358-362. doi: 10.1210/jc.2007-2013

17. Petersenn S. Medical management of Cushing’s disease. In: Swearingen B, Biller BMK, editors. Endocrine updates vol. 31: Cushing’s disease. New York: Springer; 2011. pp. 167–182.

18. Tritos NA, Biller BMK, Swearingen B. Management of Cushing disease. Nature Reviews Endocrinology. 2011;7(5):279-289. doi: 10.1038/nrendo.2011.12

19. Chow JT, Thompson GB, Grant CS, Farley DR, Richards ML, Young WF. Bilateral laparoscopic adrenalectomy for corticotrophin–dependent Cushing's syndrome: a review of the Mayo Clinic experience. Clinical Endocrinology. 2008;68(4):513-519. doi: 10.1111/j.1365-2265.2007.03082.x

20. Ritzel K, Beuschlein F, Mickisch A, Osswald A, Schneider HJ, Schopohl J, et al. Outcome of Bilateral Adrenalectomy in Cushing's Syndrome: A Systematic Review. The Journal of Clinical Endocrinology & Metabolism. 2013;98(10):3939-3948. doi: 10.1210/jc.2013-1470

21. Assié G, Bahurel H, Coste J, Silvera S, Kujas M, Dugué M-A, et al. Corticotroph Tumor Progression after Adrenalectomy in Cushing’s Disease: A Reappraisal of Nelson’s Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2007;92(1):172-179. doi: 10.1210/jc.2006-1328

22. Adler GK. Cushing's syndrome, Medscape [Internet]. [access on 2013 Feb 04]. Available from: http://emedicine.medscape.com/article/117365-overview#a0199

23. Fleseriu M, Petersenn S. Medical management of Cushing’s disease: what is the future? Pituitary. 2012;15(3):330-341. doi: 10.1007/s11102-012-0397-5

24. Fleseriu M, Biller BMK, Findling JW, Molitch ME, Schteingart DE, Gross C, et al. Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome. The Journal of Clinical Endocrinology & Metabolism. 2012;97(6):2039-2049. doi: 10.1210/jc.2011-3350

25. Castinetti F, Morange I, Jaquet P, Conte-Devolx B, Brue T. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. European Journal of Endocrinology. 2007;158(1):91-99. doi: 10.1530/eje-07-0514

26. Feelders RA, Hofland LJ. Medical Treatment of Cushing's Disease. The Journal of Clinical Endocrinology & Metabolism. 2013;98(2):425-438. doi: 10.1210/jc.2012-3126

27. Verhelst JA, Trainer PJ, Howlett TA, Perry L, Rees LH, Grossman AB, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing's syndrome. Clinical Endocrinology. 1991;35(2):169-178. doi: 10.1111/j.1365-2265.1991.tb03517.x

28. Tritos NA, Biller BM. Advances in medical therapies for Cushing's syndrome. Discov Med. 2012;13(69):171-179. PMID: 22369976

29. Pedroncelli AM. Medical Treatment of Cushing’s Disease: Somatostatin Analogues and Pasireotide. Neuroendocrinology. 2010;92(1):120-124. doi: 10.1159/000314352

30. Pivonello R, Ferone D, de Herder WW, Kros JM, Del Basso De Caro ML, Arvigo M, et al. Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors. The Journal of Clinical Endocrinology & Metabolism. 2004;89(5):2452-2462. doi: 10.1210/jc.2003-030837

31. Godbout A, Manavela M, Danilowicz K, Beauregard H, Bruno OD, Lacroix A. Cabergoline monotherapy in the long-term treatment of Cushing's disease. European Journal of Endocrinology. 2010;163(5):709-716. doi: 10.1530/eje-10-0382

32. Vilar L, Naves LA, Azevedo MF, Arruda MJ, Arahata CM, Moura e Silva L, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary. 2009;13(2):123-129. doi: 10.1007/s11102-009-0209-8

33. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, et al. Pasireotide Alone or with Cabergoline and Ketoconazole in Cushing's Disease. New England Journal of Medicine. 2010;362(19):1846-1848. doi: 10.1056/NEJMc1000094

34. van der Hoek J, Waaijers M, van Koetsveld PM, Sprij-Mooij D, Feelders RA, Schmidet HA, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. AJP: Endocrinology and Metabolism. 2005;289(2):E278-E287. doi: 10.1152/ajpendo.00004.2005

35. Chevalier N, Poullot. New options in the treatment of Cushing’s disease: a focus on pasireotide. Research and Reports in Endocrine Disorders. 2013:31. doi: 10.2147/rred.s30972

36. Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease. New England Journal of Medicine. 2012;366(10):914-924. doi: 10.1056/NEJMoa1105743

37. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. European Journal of Endocrinology. 2005;152(4):645-654. doi: 10.1530/eje.1.01876

38. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology. 2002;146(5):707-716. doi: 10.1530/eje.0.1460707

39. Batista DL, Zhang X, Gejman R, Ansell PJ, Zhou Y, Johnson SA, et al. The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism. 2006;91(11):4482-4488. doi: 10.1210/jc.2006-1245

40. Boscaro M, Ludlam WH, Atkinson B, Glusman JE, Petersenn S, Reincke M, et al. Treatment of Pituitary-Dependent Cushing’s Disease with the Multireceptor Ligand Somatostatin Analog Pasireotide (SOM230): A Multicenter, Phase II Trial. The Journal of Clinical Endocrinology & Metabolism. 2009;94(1):115-122. doi: 10.1210/jc.2008-1008

41. Boscaro M, Zhang Y, Sen K, et al. Long-term treatment of Cushing’s disease with pasireotide (SOM230): results from a Phase II extension study. European Congress of Endocrinology, Prague, 24–28 Apr 2010. Available at: http://www.endocrine-abstracts.org/ea/0022/ea0022P640.htm

42. Boscaro M, Bertherat J, Findling J, Fleseriu M, Atkinson AB, Petersenn S, et al. Extended treatment of Cushing’s disease with pasireotide: results from a 2-year, Phase II study. Pituitary. 2013;17(4):320-326. doi: 10.1007/s11102-013-0503-3

43. Bertherat J, Schopohl J, Ludlam WH, Maldonado M, Trovato A, Hughes G, et al. Long-Term Pasireotide Use Leads to Significant and Sustained Improvements in the Signs and Symptoms of Cushing Disease: 24-Month Results from a Randomized Phase III Study. Novel Medical Treatments for Pituitary Tumors (Clinical). p. SUN-734-SUN-734. Available from: http://press.endocrine.org/doi/abs/10.1210/endo-meetings.2012.NP.9.SUN-734

44. Bertherat J, Ludlam W, Pivonello R, et al. Long-term use of pasireotide in Cushing’s disease: 24-month safety results from a randomized Phase III study. Endocrine Abstracts (2012) 29 P1405. Available from: http://www.endocrine-abstracts.org/ea/0029/ea0029p1405.htm

45. Henry RR, Mudaliar S, Wetli-Hermosillo K, et al. Mechanism and management of hyperglycemia associated with pasireotide: results from studies in healthy volunteers. Endocrine Abstracts (2011) 26 P260. Available from: http://www.endocrine-abstracts.org/ea/0026/ea0026p260.htm

46. Breitschaft A, Hu K, Hermosillo Reséndiz K, Darstein C, Golor G. Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study. Diabetes Research and Clinical Practice. 2014;103(3):458-465. doi: 10.1016/j.diabres.2013.12.011

47. Reznik Y, Bertherat J, Borson-Chazot F, Brue T, Chanson P, Cortet-Rudelli C, et al. Management of hyperglycaemia in Cushing's disease: Experts’ proposals on the use of pasireotide. Diabetes and Metabolism. 2013;39(1):34-41. doi: 10.1016/j.diabet.2012.10.005

48. Colao A, De Block C, Gaztambide MS, Kumar S, Seufert J, Casanueva FF. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2013;17(2):180-186. doi: 10.1007/s11102-013-0483-3

49. Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. Clinical Endocrinology. 2014;81(3):408-417. doi: 10.1111/cen.12431